Orlistat
货号：
10005426-50mg 基本售价：
336.0 元 规格：
50 mg
产品信息
概述| 货号 | 10005426-50mg |
| 描述 | Orlistat inhibits gastric, pancreatic, and carboxyl ester lipases, preventing the hydrolysis of triglycerides to free fatty acids and monoglycerides, and as such is widely used to treat obesity.1 With a 120 mg dose before each meal in healthy subjects, orlistat is reported to accelerate gastric emptying and attenuates the secretion of glucose-dependent insulinotropic peptide without affecting plasma responses of cholecystokinin, glucagon-like peptide-1, pancreatic polypeptide, or insulin. 2 It also targets additional serine hydrolases in the nervous system, such as diacylglycerol lipase (DAGL), which is responsible for the conversion of DAG to 2-AG. Orlistat potently inhibits human recombinant DAGLα with an IC50 value of 60 nM and at 1 µM inhibits the formation of 2-AG in intact cells in vitro.3 |
| 别名 | Alli;Tetrahydrolipstatin;Xenical™; |
性能| 供应商 | Cayman |
| 应用文献 |
1.Hadváry, P.,Lengsfeld, H., and Wolfer, H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochemistry Journal 256, 357-361 (1988).
2.Enç, F.Y.,Önes, T.,Akin, H.L., et al. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. American Journal of Physiology and Gastrointestinal Liver Physiology 296, G482-G489 (2009).
3.Bisogno, T.,Cascio, M.G.,Saha, B., et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochemica et Biophysica Acta 1761, 205-212 (2006).
|
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 495.7 |
| 分子式 | C29H53NO5 |
| CAS号 | 96829-58-2 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
